title: Evaluation of the efficacy of a therapeutic HIV vaccine by in vitro stimulation assay.
abstract: A novel method for HIV vaccine efficacy evaluation was established and the experimental conditions optimized. This novel method was then applied to determine whether a recombinant adenovirus type 5 HIV therapeutic vaccine expressing Gag antigen (Ad5-HIVgag) could stimulate HIV-specific cellular responses in vitro. The results indicated that HIV-specific IFN-gama production lymphocytes were induced by the Ad5-HIVgag vaccine. Compared with other methods, this in vitro stimulation method is safe and time-efficient, and the result is more intuitive. It has the potential to be regarded as a supplement to other methods for evaluating the IFN-gamma production by PBMCs to HIV vaccination.
authors.affiliation: State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China.
authors.forename: Xiaozhou
authors.initials: X
authors.lastname: He
authors.affiliation: State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China.
authors.forename: Wandi
authors.initials: W
authors.lastname: Wang
authors.affiliation: State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China.
authors.forename: Ke
authors.initials: K
authors.lastname: Xu
authors.affiliation: State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China. Electronic address: fengxia621@126.com.
authors.forename: Xia
authors.initials: X
authors.lastname: Feng
authors.affiliation: State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China. Electronic address: zengyicdc@sina.com.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zeng
mesh_terms: D016915:AIDS Vaccines / Q000235:genetics / Q000494:pharmacology*; D062705:Adenovirus Vaccines; D000293:Adolescent; D000328:Adult; D002478:Cells, Cultured; D002681:China; D058501:Enzyme-Linked Immunospot Assay; D005260:Female; D016655:HIV Core Protein p24 / Q000235:genetics; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007371:Interferon-gamma / Q000378:metabolism; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000235:genetics; D013601:T-Lymphocytes / Q000276:immunology*; D055815:Young Adult
chemical_list: D016915:AIDS Vaccines; D062705:Adenovirus Vaccines; D016655:HIV Core Protein p24; D010446:Peptide Fragments; D007371:Interferon-gamma
keywords: Cellular immune response; HIV; In vitro experiment; Recombinant adenovirus type 5; Vaccine